The impact of milk proteins and peptides on blood pressure and vascular function: A review of evidence from human intervention studies

Nutrition Research Reviews

Volumn 26, Issue 2, 2013, Pages 177-190

  Fekete, Ágnes A ^a,b   Givens, D Ian ^b   Lovegrove, Julie A ^a  

^a UNIVERSITY OF READING   (United Kingdom)

^b School of Agriculture   (United Kingdom)

Author keywords

Blood pressure; CVD; Milk proteins; Peptides; Vascular function

Indexed keywords

CASEIN; MILK PROTEIN; PEPTIDE; MILK PEPTIDE; UNCLASSIFIED DRUG;

ANTIHYPERTENSIVE ACTIVITY; ARTERIAL STIFFNESS; BIOAVAILABILITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; DIETARY INTAKE; HUMAN; HYPERTENSION; INFORMATION RETRIEVAL; INTERVENTION STUDY; NUTRITIONAL ASSESSMENT; NUTRITIONAL HEALTH; REVIEW; WHEY; BLOOD PRESSURE; FOOD INTAKE; VASCULAR DISEASE;

BLOOD PRESSURE; CASEINS; ENDOTHELIUM, VASCULAR; HUMANS; HYPERTENSION; MILK PROTEINS; PEPTIDES; VASCULAR STIFFNESS;

EID: 84900530306     PISSN: 09544224     EISSN: 14752700     Source Type: Journal    
DOI: 10.1017/S0954422413000139     Document Type: Review

References (90)

1. Shah N (2000) Effects of milk-derived bioactives: an overview. Br J Nutr 84, 3-10.
2. Boelsma E & Kloek J (2009) Lactotripeptides and antihyper-tensive effects: a critical review. Br J Nutr 101, 776-786.
3. Geleijnse JM & Engberink MF (2010) Lactopeptides and human blood pressure. Curr Opin Lipidol 21, 58-63.
4. World Health Organization (2011) Cardiovascular diseases (CVDs) Fact sheet no. 317. http://www.who.int/mediacen-tre/factsheets/fs317/en/index.html (accessed January 2011)
5. British Heart Foundation (2010) Coronary heart disease statistics 2010 http://www.bhf.org.uk/publications/view-publication.aspx?ps=1001546 (accessed December 2011)
6. Lovegrove J & Jackson K (2011) Functional foods and coronary heart disease. In Functional Foods: Concept to Product, 2nd ed., pp. 153-201 [M Saarela, editor]. Oxford: Woodhead Publishing Limited.
7. World Health Organization (2009) Global health risk: mortality and burden of disease attributable to selected major risks http://www.who.int/healthinfo/ global-burden-disease/GlobalHealthRisks-report-full.pdf (accessed January 2011)
8. Kearney PM, Whelton M, Reynolds K., et al (2005) Global burden of hypertension: analysis of worldwide data. Lancet 365, 217-223.
9. Schachinger V, Britten M & Zeiher A (2000) Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 101, 1899-1906.
10. Verma S & Anderson TJ (2002) Fundamentals of endothelial function for the clinical cardiologist. Circulation 105, 546-549.
11. Corretti MC, Anderson TJ, Benjamin E.J., et al (2002) Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 39, 257-265.
12. Turner J, Belch JJ & Khan F (2008) Current concepts in assessment of microvascular endothelial function using laser Doppler imaging and iontophoresis. Trends Cardiovasc Med 18, 109-116.
13. Brodsky SV, Gealekman O, Chen J., et al (2004) Prevention and reversal of premature endothelial cell senescence and vasculopathy in obesity-induced diabetes by ebselen. Circ Res 94, 377-384.
14. Morris SJ & Shore AC (1996) Skin blood flow responses to the iontophoresis of acetylcholine and sodium nitroprusside in man: possible mechanisms. J Physiol 496, 531-542.
15. Payne RA & Webb DJ (2006) Arterial blood pressure and stiffness in hypertension: is arterial structure important? Hypertension 48, 366-367.
16. Boutouyrie P, Tropeano AI, Asmar R, et al (2002) Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension 39, 10-15.
17. Franklin SS (2005) Arterial stiffness and hypertension: a two-way street? Hypertension 45, 349-351.
18. Stewart AD, Jiang B, Millasseau S.C., et al (2006) Acute reduction of blood pressure by nitroglycerin does not normalize large artery stiffness in essential hypertension. Hypertension 48, 404-410.
19. Wilkinson IB, Qasem A, McEniery C.M., et al (2002) Nitric oxide regulates local arterial distensibility in vivo. Circulation 105, 213-217.
20. Rhee M, Lee H & Park J (2008) Measurements of arterial stiffness: methodological aspects. Korean Circ J 38, 343-350.
21. Swampillai J, Doshi S, Fraser A., et al (2005) Review: Clinical assessment of endothelial function - an update. Br J Diabetes Vasc Dis 5, 72-76.
22. Kelly RP, Millasseau SC, Ritter J.M., et al (2001) Vasoactive drugs influence aortic augmentation index independently of pulse-wave velocity in healthy men. Hypertension 37, 1429-1433.
23. Whitworth JA (2003) World Health Organization (WHO)/ International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 21, 1983-1992.
24. Givens DI (2012) Milk in the diet: good or bad for vascular disease? Proc Nutr Soc 71, 98-104.
25. Lorenzen JK & Astrup A (2011) Dairy calcium intake modifies responsiveness of fat metabolism and blood lipids to a high-fat diet. Br J Nutr, (epublication ahead of print version 31 January 2011).
26. Elwood PC, Pickering JE, Givens D.I., et al (2010) The consumption of milk and dairy foods and the incidence of vascular disease and diabetes: an overview of the evidence. Lipids 45, 925-939.
27. Beydoun MA, Gary TL, Caballero B.H., et al (2008) Ethnic differences in dairy and related nutrient consumption among US adults and their association with obesity, central obesity, and the metabolic syndrome. Am J Clin Nutr 87, 1914-1925.
28. Engberink MF, Hendriksen MA, Schouten E.G., et al (2009) Inverse association between dairy intake and hypertension: the Rotterdam Study. Am J Clin Nutr 89, 1877-1883.
29. Crichton GE, Elias MF, Dore G.A., et al (2012) Relations between dairy food intake and arterial stiffness: pulse wave velocity and pulse pressure. Hypertension 59, 1044-1051.
30. Korhonen H & Pihlanto A (2006) Bioactive peptides: production and functionality. Int Dairy J 16, 945-960.
31. Kitts DD & Weiler K (2003) Bioactive proteins and peptides from food sources. Applications of bioprocesses used in isolation and recovery. Curr Pharm Des 9, 1309-1323.
32. Hartmann R & Meisel H (2007) Food-derived peptides with biological activity: from research to food applications. Curr Opin Biotechnol 18, 163-169.
33. Nakamura Y, Yamamoto N, Sakai K., et al (1995) Purification and characterization of angiotensin I-converting enzyme inhibitors from sour milk. J Dairy Sci 78, 777-783.
34. Fekete AA, Givens DI & Lovegrove JA (2013) Effects of casein-derived lactotripeptides on blood pressure: a meta-analysis of randomized controlled trials in humans. J Hypertens, (In the Press).
35. Pal S & Ellis V (2010) The chronic effects of whey proteins on blood pressure, vascular function, and inflammatory markers in overweight individuals. Obesity 18, 1354-1359.
36. Pal S & Ellis V (2011) Acute effects of whey protein isolate on blood pressure, vascular function and inflammatory markers in overweight postmenopausal women. Br J Nutr 105, 1512-1519.
37. Ashar MN & Chand R (2004) Fermented milk containing ACE-inhibitory peptides reduces blood pressure in middle aged hypertensive subjects. Milchwissenschaft 59, 363-366.
38. Sekiya S, Kobayashi Y, Kita E., et al (1992) Antihypertensive effects of tryptic hydrolysate of casein on normotensive and hypertensive volunteers. J Nutr Food Sci 45, 513-517.
39. Sugai R (1998) ACE inhibitors and functional foods. Bull IDF 336, 17-20.
40. Karaki H, Doi K, Sugano S., et al (1990) Antihypertensive effect of tryptic hydrolysate of milk casein in spontaneously hypertensive rats. Comp Biochem Physiol C 96, 367-371.
41. Townsend RR, McFadden CB, Ford V, et al (2004) A randomized, double-blind, placebo-controlled trial of casein protein hydrolysate (C12 peptide) in human essential hypertension. Am J Hypertens 17, 1056-1058.
42. Cadée J.A., Chang CY, Chen C.W., et al (2007) Bovine casein hydrolysate (C12 peptide) reduces blood pressure in prehy-pertensive subjects. Am J Hypertens 20, 1-5.
43. Hodgson JM, Zhu K, Lewis J.R., et al (2012) Long-term effects of a protein-enriched diet on blood pressure in older women. Br J Nutr 107, 1664-1672.
44. Kawase M, Hashimoto H, Hosoda M., et al (2000) Effect of administration of fermented milk containing whey protein concentrate to rats and healthy men on serum lipids and blood pressure. J Dairy Sci 83, 255-263.
45. Fluegel SM, Shultz TD, Powers J.R., et al (2010) Whey beverages decrease blood pressure in prehypertensive and hypertensive young men and women. Int Dairy J 20, 753-760.
46. Lee YM, Skurk T, Hennig M., et al (2007) Effect of a milk drink supplemented with whey peptides on blood pressure in patients with mild hypertension. Eur J Nutr 46, 21-27.
47. Hirota T, Ohki K, Kawagishi R., et al (2007) Casein hydroly-sate containing the antihypertensive tripeptides Val-Pro-Pro and Ile-Pro-Pro improves vascular endothelial function independent of blood pressure-lowering effects: contribution of the inhibitory action of angiotensin-converting enzyme. Hypertens Res 30, 489-496.
48. Yoshizawa M, Maeda S, Miyaki A., et al (2010) Additive beneficial effects of lactotripeptides intake with regular exercise on endothelium-dependent dilatation in postmenopausal women. Am J Hypertens 23, 368-372.
49. Yoshizawa M, Maeda S, Miyaki A., et al (2009) Additive beneficial effects of lactotripeptides and aerobic exercise on arterial compliance in postmenopausal women. Am J Physiol Heart Circ Physiol 297, H1899-H1903.
50. Jauhiainen T, Ronnback M, Vapaatalo H., et al (2010) Long-term intervention with Lactobacillus helveticus fermented milk reduces augmentation index in hypertensive subjects. Eur J Clin Nutr 64, 424-431.
51. Jauhiainen T, Ronnback M, Vapaatalo H., et al (2007) Lactobacillus helveticus fermented milk reduces arterial stiffness in hypertensive subjects. Int Dairy J 17, 1209-1211.
52. Turpeinen AM, Ehlers PI, Kivimaki A.S., et al (2011) Ile-Pro-Pro and Val-Pro-Pro tripeptide-containing milk product has acute blood pressure lowering effects in mildly hypertensive subjects. Clin Exp Hypertens 33, 388-396.
53. Turpeinen AM, Kumpu M, Ronnback M., et al (2009) Antihypertensive and cholesterol-lowering effects of a spread containing bioactive peptides IPP and VPP and plant sterols. J Func Food 1, 260-265.
54. Nakamura T, Mizutani J, Ohki K., et al (2011) Casein hydrolysate containing Val-Pro-Pro and Ile-Pro-Pro improves central blood pressure and arterial stiffness in hypertensive subjects: a randomized, double-blind, placebo-controlled trial. Atherosclerosis 219, 298-303.
55. Cicero AF, Rosticci M, Gerocarni B., et al (2011) Lactotripep-tides effect on office and 24-h ambulatory blood pressure, blood pressure stress response, pulse wave velocity and cardiac output in patients with high-normal blood pressure or first-degree hypertension: a randomized double-blind clinical trial. Hypertens Res 34, 1035-1040.
56. Ballard KD, Bruno RS, Seip R.L., et al (2009) Acute ingestion of a novel whey-derived peptide improves vascular endo-thelial responses in healthy individuals: a randomized, placebo controlled trial. Nutr J 8, 34.
57. Ballard KD, Kupchak BR, Volk B.M., et al (2013) Acute effects of ingestion of a novel whey-derived extract on vascular endothelial function in overweight, middle-aged men and women. Br J Nutr 109, 882-893.
58. Mancia G, Ferrari A, Gregorini L., et al (1983) Blood pressure and heart rate variabilities in normotensive and hypertensive human beings. Circ Res 53, 96-104.
59. Mancia G, De Backer G, Dominiczak A, et al (2007) 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 28, 1462-1536.
60. Drøyvold W.B., Midthjell K, Nilsen T.I., et al (2005) Change in body mass index and its impact on blood pressure: a prospective population study. Int J Obes 29, 650-655.
61. Sato R, Noguchi T & Naito H (1986) Casein phosphopep-tide (CPP) enhances calcium absorption from the ligated segment of rat small intestine. J Nutr Sci Vitaminol 32, 67-76.
62. Chess DJ, Lei B, Hoit B.D., et al (2007) Deleterious effects of sugar and protective effects of starch on cardiac remodeling, contractile dysfunction, and mortality in response to pressure overload. Am J Physiol Heart Circ Physiol 293, H1853-H1860.
63. Dai S & McNeill JH (1995) Fructose-induced hypertension in rats is concentration- and duration-dependent. J Pharmacol Toxicol Methods 33, 101-107.
64. Sharma N, Okere IC, Barrows B.R., et al (2008) High-sugar diets increase cardiac dysfunction and mortality in hypertension compared to low-carbohydrate or high-starch diets. J Hypertens 26, 1402-1410.
65. Murray BA & FitzGerald RJ (2007) Angiotensin converting enzyme inhibitory peptides derived from food proteins: biochemistry, bioactivity and production. Curr Pharm Des 13, 773-791.
66. Saito T (2008) Antihypertensive peptides derived from bovine casein and whey proteins. Adv Exp Med Biol 606, 295-317.
67. Costa ED, Gontijo JD & Netto F (2007) Effect of heat and enzymatic treatment on the antihypertensive activity of whey protein hydrolysates. Int Dairy J 17, 632-640.
68. Sipola M, Finckenberg P, Korpela R., et al (2002) Effect of long-term intake of milk products on blood pressure in hypertensive rats. J Dairy Res 69, 103-111.
69. Rutherfurd-Markwick KJ & Moughan PJ (2005) Bioactive peptides derived from food. J AOAC Int 88, 955-966.
70. Meisel H (1997) Biochemical properties of bioactive peptides derived from milk proteins: Potential nutraceuticals for food and pharmaceutical applications. Livest Prod Sci 50, 125-138.
71. Usinger L, Ibsen H, Linneberg A., et al (2010) Human in vivo study of the renin-angiotensin-aldosterone system and the sympathetic activity after 8 weeks daily intake of fermented milk. Clin Physiol Funct Imaging 30, 162-168.
72. Loukas S, Varoucha D, Zioudrou C., et al (1983) Opioid activities and structures of α-casein-derived exorphins. Biochemistry 22, 4567-4573.
73. Chang KJ, Cuatrecasas P, Wei E.T., et al (1982) Analgesic activity of intracerebroventricular administration of morphiceptin and β-casomorphins: correlation with the morphine (micro) receptor binding affinity. Life Sci 30, 1547-1551.
74. Matthies H, Stark H, Hartrodt B., et al (1984) Derivatives of β;-casomorphins with high analgesic potency. Peptides 5, 463-470.
75. Nurminen ML, Sipola M, Kaarto H., et al (2000) α-Lactorphin lowers blood pressure measured by radiotelemetry in normotensive and spontaneously hypertensive rats. Life Sci 66, 1535-1543.
76. Dickinson HO, Nicolson DJ, Cook J.V., et al (2006) Calcium supplementation for the management of primary hypertension in adults The Cochrane Database of Systematic Reviews 2006, issue 2, CD004639. http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD004639/frame. html
77. Hatton DC & McCarron DA (1994) Dietary calcium and blood pressure in experimental models of hypertension. Hypertension 23, 513-530.
78. de Champlain J., Wu R, Girouard H., et al (2004) Oxidative stress in hypertension. Clin Exp Hypertens 26, 593-601.
79. Rodrigo R, Prat H, Passalacqua W., et al (2007) Relationship between oxidative stress and essential hypertension. Hypertens Res 30, 1159-1167.
80. Rival SG, Boeriu CG & Wichers HJ (2001) Caseins and casein hydrolysates. 2. Antioxidative properties and relevance to lipoxygenase inhibition. J Agric Food Chem 49, 295-302.
81. Hernandez-Ledesma B., Davalos A, Bartolome B., et al (2005) Preparation of antioxidant enzymatic hydrolysates from a-lactalbumin and β-lactoglobulin. Identification of active peptides by HPLC-MS/MS. J Agric Food Chem 53, 588-593.
82. Pihlanto A (2006) Antioxidative peptides derived from milk proteins. Int Dairy J 16, 1306-1314.
83. Szabó C, Ischiropoulos H & Radi R (2007) Peroxynitrite: biochemistry, pathophysiology and development of therapeutics. Nat Rev Drug Discov 6, 662-680.
84. Vermeirssen V, Van Camp J & Verstraete W (2004) Bio-availability of angiotensin I converting enzyme inhibitory peptides. Br J Nutr 92, 357-366.
85. Masuda O, Nakamura Y & Takano T (1996) Antihypertensive peptides are present in aorta after oral administration of sour milk containing these peptides to spontaneously hypertensive rats. J Nutr 126, 3063-3068.
86. Foltz M, Cerstiaens A, van Meensel A, et al (2008) The angiotensin converting enzyme inhibitory tripeptides Ile-Pro-Pro and Val-Pro-Pro show increasing permeabilities with increasing physiological relevance of absorption models. Peptides 29, 1312-1320.
87. Wuerzner G, Peyrard S, Blanchard A., et al (2009) The lactotripeptides isoleucine-proline-proline and valine-pro-line-proline do not inhibit the N-terminal or C-terminal angiotensin converting enzyme active sites in humans. J Hypertens 27, 1404-1409.
88. Vermeirssen V, Van Camp J, Decroos K, et al (2003) The impact of fermentation and in vitro digestion on the formation of angiotensin-I-converting enzyme inhibitory activity from pea and whey protein. J Dairy Sci 86, 429-438.
89. Vermeirssen V, Van Camp J, Devos L, et al (2003) Release of angiotensin I converting enzyme (ACE) inhibitory activity during in vitro gastrointestinal digestion: from batch experiment to semicontinuous model. J Agric Food Chem 51, 5680-5687.
90. Murakami M, Tonouchi H, Takahashi R., et al (2004) Structural analysis of a new anti-hypertensive peptide (β-lactosin B) isolated from a commercial whey product. J Dairy Sci 87, 1967-1974.